RxDoctor Payments DataLook up a doctor →

Kevin Hargrave, MD

Neurology · Lafayette, LANPI 1043292600

Payments from drug & device makers

$21,086in general payments, 2019–2025

Across 1,214 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Acadia Pharmaceuticals Inc$2K
  • Jazz Pharmaceuticals Inc.$2K
  • Biogen$1K
  • UCB, Inc.$1K
  • Eisai Inc.$1K
  • plus $11K from 54 others

What the payments were for

  • Consulting fees$8004%
  • Speaking & faculty fees$290%
  • Food & beverage$19,74094%
  • Education$5172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)230$3,038
Acadia Pharmaceuticals Inc213$2,127
Jazz Pharmaceuticals Inc.80$1,552
Biogen46$1,170
UCB, Inc.57$1,064
Eisai Inc.40$1,000
Sanofi41$806
Amgen(2 entities)40$771
AstraZeneca36$742
Medtronic(2 entities)21$728
EMD Serono, Inc.24$627
SK Life Science, Inc.25$595
Vertex1$500
Mallinckrodt Hospital Products Inc.17$390
Avanir Pharmaceuticals, Inc.32$371
Argenx US, Inc.11$369
TG Therapeutics, Inc.14$363
Lundbeck LLC20$345
Teva Pharmaceuticals USA, Inc.25$312
Axsome Therapeutics, Inc.8$279
Neurocrine Biosciences, Inc.15$252
Novartis14$247
Bristol Myers Squibb11$238
Adamas Pharmaceuticals, Inc.15$219
CSL Behring13$215
Amneal Pharmaceuticals LLC20$184
Kyowa Kirin, Inc.13$182
Neurelis, Inc.10$177
Vanda Pharmaceuticals Inc.5$174
Abbott2$161
Biohaven Pharmaceuticals, Inc.13$155
Pfizer9$146
Mallinckrodt Enterprises LLC10$145
Supernus Pharmaceuticals, Inc.16$141
Johnson & Johnson(2 entities)5$119
Grifols USA, LLC4$108
E.r. Squibb & Sons, L.L.C.4$106
Idorsia Pharmaceuticals US Inc1$104
MDD US Operations, LLC7$100
Harmony Biosciences LLC3$98
GE HealthCare4$74
Merz Pharmaceuticals, LLC3$59
Vertical Pharmaceuticals, LLC3$52
ANI Pharmaceuticals, Inc.3$47
Tanabe Pharma America, Inc.3$44
Acorda Therapeutics, Inc3$44
Springworks Therapeutics, Inc.2$36
Otsuka America Pharmaceutical, Inc.2$32
Genentech USA, Inc.2$31
Boston Scientific2$30
Takeda Pharmaceuticals U.S.A., Inc.2$29
Zyla Life Sciences, Inc.2$26
Assertio Therapeutics, Inc.2$25
Lilly USA, LLC2$24
Shire North American Group Inc2$24
Inspire Medical Systems, Inc.1$20
Cycle Pharmaceuticals Inc1$19
Neural Analytics, Inc.1$17
Greenwich Biosciences, Inc.1$14
Impel Pharmaceuticals Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,086 in reported general payments places this provider in the 80th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana

Medicare billing

Part B allowed, 2024
$169,196
Medicare patients
902
Services billed
1,710

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate44$232,844
FycompaPerampanel41$48,339
RytaryCarbidopa/Levodopa54$46,555
NeuproRotigotine19$30,546
VimpatLacosamide19$26,218
Tetrabenazine12$22,602
Keppra XrLevetiracetam12$18,565
SunosiSolriamfetol Hcl11$9,217
Carbidopa-LevodopaCarbidopa/Levodopa321$9,070
Lacosamide40$5,367
Levetiracetam152$4,019
Memantine Hcl109$3,719
Lamotrigine OdtLamotrigine11$3,671
CarbatrolCarbamazepine11$3,072
Dimethyl Fumarate19$2,825

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$2,127$232,84444 claims
UCB, Inc.Neupro, Vimpat$1,064$56,76438 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$184$48,51281 claims
Eisai Inc.Fycompa$1,000$48,33941 claims
Axsome Therapeutics, Inc.Sunosi$279$9,21711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 225 neurology providers in Louisiana.

Other neurology in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →